Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms EPD 301, EPD301, GX-BP1 + [1] |
Target |
Action degraders |
Mechanism SOX2 degraders(SRY-box transcription factor 2 degraders) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| squamous cell lung carcinoma | Preclinical | South Korea | 16 Oct 2024 | |
| squamous cell lung carcinoma | Preclinical | South Korea | 16 Oct 2024 | |
| Neoplasms | Preclinical | South Korea | 08 Apr 2024 |





